Bristol-Myers Squibb Company
ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF

Abstract:

The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of ANGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity e.g., cardiovascular-related diseases or disorders.